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List of abreviations 
ACN : Anterior commissural nucleus 
AL : Ansa lenticularis 
ATG : Adenine, Thymine, Guanine 
AUG : Adenine, Uracil, Guanine 
BST : Bed nucleus of the stria terminalis 
BW : Body weight  
cDNA : Complementary deoxyribonucleic acid 
cDNAs : Complementary deoxyribonucleic acids 
CNS : Central nervous system 
DI : Diabetes insipidus  
DNA : Deoxyribonucleic acid 
H2O2 : Hydrogen peroxide 
HCL : Hydrochloric acid 
HNS : Hypothalamo-neurohypophyseal system 
HPLC : High Performance Liquid Chromatography 
i.c.v : Intracerebroventricular 
IgG : Immunoglobulin G 
ispi : Intersupraoptic-paraventricular islands 
LSN : Lateral subcommissural nucleus (LSN=ACN) 
M oligos : Methylphosphonate oligos 
mpoa : Medial preoptic area 
mRNA : Messenger ribonucleic acid 
NaCl : Sodium Chloride 
NP : Neurophysin 
ODN : Oligodeoxynucleotide 
ODNs : Oligodeoxynucleotides 
oligo : Oligodeoxynucleotide  
OT : Oxytocin 
OVLT : Organum vasculosum of the lamina terminalis 
P oligos : Phosphodiester ODNs 
PBS : Phosphate buffer saline 
Pe : Periventricular nucleus 
 IV 
pf : Perifornical region 
PVN : Paraventricular nucleus 
RNA : Ribonucleic acid 
Rnase-H : Ribonuclease H 
RT PCR : Real time polymerase chain reaction 
S oligos : Phosphorothioates oligos 
SCN : Suprachiasmatic nucleus 
SON : Supraoptic nucleus 
V2 : Vasopressin 2 (receptor) 
V2R : Vasopressin 2 receptor 
VP : Vasopressin 
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9. EHRENWÖRTLICHE ERKLÄRUNG 
 




The impact of certain therapeutic agents, whose mechanism of action is based on its 
influence over the genetic code could certainly revolutionize contemporary 
pharmacology. Antisense targeting, or antisense strategies are among the several 
proposed approaches. This technology theoretically offers the exciting possibility of 
selectively modifying the expression of a particular gene without affecting the function 
of others (Akhtar and Juliano, 1992). Such selective inhibition of a gene expression 
allows the study of physiological and pathophysiological cellular processes on a 
molecular basis (Schlingensiepen and Schlingensiepen, 1997). The first definitive 
demonstration of a block in translation due to the use of antisense RNA in cell-free 
extracts was carried out in 1963 by Singer, Jones, and Nirenberg (Pestka, 1992). 
However, it was not until 1978 that this novel concept became popular with the work of 
Zamecnik and Stepheson. At that time, these authors published their results on 
blocking the replication of Rous Sarcoma Virus in infected chicken fibroblasts by 
adding a synthetically assembled oligodeoxynucleotide (oligo) directed against a 
specific sequence of a viral genome (Zamecnik and Stepheson, 1978). Since then, 
these pioneering works and many subsequent studies have shown impressive results 
about the effects of this technology modulating biological processes. In the last few 
years, the antisense technology has been considered not only a useful tool to  study a 
gene function but also it aroused interest about  its possible use as therapeutic agents 
to treat many diseases (Sharma and Narayanan, 1995; Galderisi, Cascino and, 
Giordano, 1999). The possibility of blocking specific gene expression without multiple 
side effects projects towards drugs of a new generation, which would exert their action 
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at the molecular level (Monteith and Levin, 1999), hence some authors have 
considered  antisense strategies, as the "magic bullet" for the treatment of certain 
illnesses (Stein and Cheng 1993; Ma and Doan, 1994).  
 
Antisense therapeutics using synthetic oligodeoxynucleotides (ODNs) are currently 
being evaluated in clinical trials for cancer, inflammation, and viral diseases (Monteith 
and Levin, 1999; Yuen et al., 1999; Nemunaitis et al., 1999). In neuropharmacology, 
antisense technology has also become a very valuable tool to block the expression of 
specific genes in vitro as well as in the intact brain of animals (Heilig and 
Schlingensiepen, 1996). A potential future use of this technique on the central nervous 
system (CNS) of humans could include several neurological disorders (Telleria-Diaz, 
2000) such as Brain tumors (Engelhard, http://www.moffitt.usf.edu 
/cancjrnl/v5n2/article7.html), the ischemic  Stroke (Wahlestedt et al., 1993), and some 
neurodegenerative disorders like Alzheimer or Parkinson disease (Soreq and Seidman, 
2000; Van Kampen, McGeer, and Stoessl, 2000). However, it should be pointed out 
that the actual cascade of cellular and molecular events in antisense targeted tissues 
is still highly hypothetical to date. On the other hand, there is little information regarding 
the side effects these compounds could produce during a long term administration. 
Therefore more investigations are required before the introduction of this therapeutic 
modality on the human CNS can be implemented. 
 
1.1 The antisense concept. 
 
Cell must synthesize proteins by means of the expression of thousands of genes to 
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maintain its function. The specific information of each gene is encoded in the DNA. To 
be expressed, a gene is transcribed from the DNA  into messenger RNA (mRNA) and 
subsequently translated into the corresponding protein (Schlingensiepen and 
Schlingensiepen, 1997). The DNA molecule consists of two associated polynucleotide 
strands that wind together in a helical fashion. DNA has a sense strand (5’→ 3’), which 
encodes the synthesis of a protein; the complementary strand is antisense (3’→5’), 
and it does not code for the synthesis of any protein.  The single stranded Pre-mRNA is 
copied from the antisense strand and has the same sequence of nucleotides as the 
sense strand of DNA except that the thymine is replaced by uracil. A short 
complementary synthetic antisense oligo will hybridize to the mRNA leading to a 
translational arrest (Phillips and Gyurko, 1997 ) (Fig.1). Non-homologous or 
mismatched sequences of other genes do not form stable enough hybrids for the 
antisense oligo to inhibit protein translation. Thus, it is possible to target a unique 
sequence present in a single gene. Since by definition, the mRNA is the ”sense” strand, 
any complementary sequence is ”antisense” to it. The antisense orientation is a 
prerequisite for sequence-specific inhibition of translation, therefore this term is 












Fig1. An antisense ODN contains the same bases sequence as the DNA no coding strand. 
 
1.2 Uptake and intracellular fate of antisense ODNs. 
 
The pioneering work of Zamecnik and Stephenson, and many other further studies 
demonstrate that despite their large size  and polar nature, oligonucleotides do indeed 
enter cells. However, ODNs in their natural form have a phosphodiester backbone that 
renders them subject to rapid degradation in the blood, intracellular fluid, or 
cerebrospinal fluid by exo- and endonucleases. The half-life of phosphodiester ODNs 
(P oligos) is in the range of minutes in blood and tissue culture media. In cerebrospinal 
fluid, the half-life of ODNs is a few hours (Phillips and Gyurko, 1997 ), therefore several 
chemical modifications have been proposed to prolong the half life of ODNs in 




Fig.2. Since unmodified DNA oligonucleotides are very unstable in the biological milieu, a number of 
number of structural analogues have been developed with improved stability towards nucleases. 
Backbone-modified ODN analogues include the phosphorothioates (S-oligos), methylphosphonates 
(M-oligos), and phosphoramidates (NR-oligos) among others.  
 
The first significant investigations on the mechanism of cellular uptake of DNA 
oligonucleotides (with P oligos) showed that these probably bind to a specific cell 
surface binding protein before being internalized by endocytosis (Akhtar and Juliano, 
1992). The existence of a specific cell surface receptor for uptake of P oligos by 
endocytosis was also confirmed by other authors (Yakubov et al, 1989). 
Phosphorothioate oligos (S oligos) are also thought to enter cells by receptor mediated 
endocytosis. Using phosphorothioate homopolymers conjugated to a fluorescent 
acridine at the 5’-end, it was demonstrated that uptake of S oligos was somewhat 
slower than that of corresponding P oligos, but was dependent on chain length, with 
shorter S oligos being taken up faster than longer ones (Stein et al., 1988). Since 
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methylphosphonate oligos (M oligos) are neutral and fairly hydrophobic, these 
molecules were initially thought to enter cells by passive diffusion, but certain studies 
suggest that this is unlikely to be their predominant mode of cellular uptake (Akhtar and 
Juliano, 1992). A study assessing efflux (transport) kinetics of M oligos across model 
membranes (liposomes) showed that they were transported across model membranes 
at similar rates to P oligos and S oligos -thought to enter cells via endocytosis- (Akhtar 
S et al., 1991). 
Upon cellular entry and escape from endosomal compartments, ODNs migrate to the 
cytoplasm and nucleus. However, it is unlikely that they exert their action solely in the 
nucleus because antisense activity has been observed with oligomers targeted to 
vesicular stomatitis virus, whose replication cycle is entirely cytoplasmic (Lemaitre, 
Bayard and Lebleu, 1987; Kulka et al., 1989). 
 
1.3 Pharmacokinetics of antisense ODNs. 
 
Comparison of different antisense oligo compounds shows that pharmacokinetics 
depend on the chemistry and to a lesser extent on length or sequence. P oligos are 
degraded rapidly in the plasma with a half-life of about 5 min if injected intravenously 
into monkeys (Agrawal, Temsamani and Tang, 1991) or rats (Inagaki et al., 1992). 
After 14 min the entire dose is degraded so that organ uptake of the intact compound is 
virtually impossible (Schlingensiepen and Schlingensiepen, 1997). The half-life of M 
oligos in mice plasma is 6 min for body distribution and 17 min for elimination (Chen et 
al., 1990). 
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Intravenously administered S oligos are cleared from plasma biphasically with an 
alpha phase of about 50 min and a beta phase of 40 hours. Initial short half-life is due 
to distribution into most major organs, with the brain having the lowest concentration. S 
oligos are then slowly eliminated from the body, primarily with urine. Up to 30% is 
excreted within 24 hours and 70% within 10 days after single administration. Up to 10% 
is excreted in the faeces. Constant plasma concentrations are obtainable by one daily 
injection. S oligos are very stable in all tissues except liver and spleen where 50% of 
any particular S-ODN is degraded within 2 days. Breakdown products appear to be 
eliminated preferentially since almost no intact oligo is found in the urine whilst plasma 
contains predominantly undegraded oligo (Schlingensiepen and Schlingensiepen, 
1997).  
Since ODNs enters the brain only in minute quantities after intravenous, subcutaneous, 
or intraperitoneal administration (Engelhard, http://www.moffitt.usf.edu 
/cancjrnl/v5n2/article7.html), there are two main strategies for applying ODNs to brain 
tissue. One is to infuse ODN into cerebral ventricles, and the second is to inject them 
intracerebrally (Szklarczyk and Kaczmarek, 1995). While a P oligo (unmodified oligo) 
was rapidly degraded following intra-ventricular injection, a S oligo remained stable 
(Whitesell L et al., 1993). In another study (Yaida and Nowak, 1995), a P oligo 
exhibited a limited and strictly periventricular distribution after intraventricular 
administration. In contrast the S oligo showed significant penetration into and 
accumulation within brain, with extensive uptake in ipsilateral striatum and dorsal 




1.4 Mechanism of action of the antisense ODNs. 
 
Although the exact mechanisms of antisense ODNs is still not known, there are at least 
5 different mechanisms proposed which include: 1) Inhibition of translation by hybrid 
formation that inhibits peptide synthesis; 2) formation of a ribonuclease H (RNase-H) 
substrate; 3) inhibition of mRNA transport from nucleus to cytoplasm because of a 
partially double-stranded structure formation; 4) inhibition of RNA processing by 
interference of splicing events; 5) triplehelix formation (Akhtar and Juliano, 1992; 
Phillips and Gyurko, 1997; Schlingensiepen and Schlingensiepen, 1997) (Fig.3). 
 
 
Fig.3. Principle of antisense inhibition. Right: normal gene activity in which mRNA is produced in 
nucleus and transported to cytoplasm where it enters ribosome and dictates sequence of amino acids to 
form a protein. Left: in principle ODN should bind to mRNA and prevents translation of message for 
proteins from ribosome assembly (3). Alternatively, antisense ODN can produce triple-helix formation 
(1), hybridization to formed mRNA preventing its transport from the nucleus to cytoplasm (2), or 
destruction in cytoplasm of the mRNA by the RNase stimulation (4). 
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Antisense inhibition could be considered as another example of the pharmacological 
receptor theory where, the ODN is the drug and the target sequence is the receptor, in 
this case, the concept relies on the strength and efficiency of specific base-pairing to 
mRNA through Watson-Crick hybridization. For binding to occur between the two, a 
minimum level of affinity is required based on the hydrogen bonding between base 
pairs. To achieve pharmacological activity, a minimum number of 15 bases provides a 
minimum level of affinity (Crooke, 1993). Increasing the length of the antisense should 
result in a higher level of specificity, but there is an upper limit of ~25-30 nucleotides 
above which ODNs are not incorporated effectively by cells. Therefore, instead of 
increasing length, it is best to test the specificity of the antisense sequence against the 
genetic database (GenBank) for possible cross-reaction with sequences other than the 
target sequences (Phillips and Gyurko, 1997). 
Antisense ODNs are designed and synthesized in the hope they recognize specific 
nucleic acid sequences contained within a mRNA, so that they bind predominantly to 
cytosolic mRNA sense strands through hydrogen bonding to complementary nucleic 
acid bases, then, the  resulting hybrid could not be translated into the encoded protein 
(translational arrest) because either translation initiation is inhibited or double strand is 
a substrate for RNase H. Both mechanisms are thought to lead to a selective inhibition 
of protein synthesis.  However it should be pointed out that evidences for a specific 
translation arrest have been provided by several studies showing that the antisense 
oligos can block the synthesis of a single protein without reducing the level of the 
correspondent mRNA (Boiziau  et al., 1991; Brysch et al, 1994). In vivo, the importance 
of RNase H for the antisense effect remains to be proven for most cell types 
(Schlingensiepen and Schlingensiepen, 1997). High RNase H activity naturally occurs 
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in tissues of very high proliferative activity like embryonic tissue or oocytes (Dagle, 
Weeks and Walder, 1991). However, in other cell-types the role of the enzyme appears 
to be minor. It has been demonstrated, in various non-embryonic cultured cells, that 
down regulation of protein translation is not enhanced by degradation of the  respective 
mRNA even after exogenous addition of RNase H (Schlingensiepen and 
Schlingensiepen, 1997). 
 
1.5 Design of antisense agents and target selection. 
 
ODNs can be designed to target different parts of the DNA-RNA machinery. To make 
an ODN that will be effective, the conventional wisdom is that it has to be at least 11-15 
nucleotides long but not longer than 20-25 nucleotides. Longer sequences decrease 
uptake into cells and shorter sequences lack specificity (Phillips and Gyurko, 1997). 
However, other authors (Schlingensiepen and Schlingensiepen, 1997) remark that the 
minimum length of an oligo has to be 12 bases to recognize a single specific sequence 
in the genome. This assumption is based on the estimated number of base pairs in the 
human genome and a random distribution of bases. For them, it would be more difficult 
to define a maximal length for an antisense compound since its uptake is time and 
temperature dependent and it is also influenced by cell type, cell culture conditions, 
media and sequence, etc. Furthermore, it has been shown that antisense  molecules of 
more than 30 bases trigger a genetic cascade of cellular antiviral response (Manche et 
al, 1992). 
A straightforward way to design an antisense ODN is to target the initiation codon 
(AUG) and the neighboring bases and compare them with a sequence upstream (5’ 
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end) and downstream (3’ end) from that site. The initiation codon of the mRNA is the 
site that triggers protein production as the message is translated into amino acids in 
the ribosomes. This strategy is also convenient because the majority of the cDNAs 
reported in the GenBank contain the AUG region. Therefore one may access the 
selected DNA on GenBank and begin by localizing the initiation codon DNA triplet 
(ATG). Then, a 15-18 sequence of bases overlapping the site (e.g., -1 to +14) is 
chosen, one upstream (e.g., -20 to -35) and  one downstream (e.g., +63 to +77). The 
complementary bases of the selected sequence from 5’ to 3’ are read to give the  
antisense sequence in the 5’ to 3’ direction; then the antisense sequence is 
synthesized by an ODN manufacturer (Phillips and Gyurko, 1997). 
Although typically the coding region is targeted, sometimes, it does not work; in 
addition, many other targets can be inhibited equally or more efficiently by ODNs 
targeted to sequences located further downstream in the coding region (West and 
Cooke, 1991; Jachimczak, 1993; Spampinato et al., 1994). Examples of non-coding 
targeted regions would be untranslated or intron sequences; or to the border region 
between these and the coding sequence (Heilig and Schlingensiepen, 1996). 
 
1.6 Toxicological properties of the ODNs. 
 
 A significant number of ODNs have now been evaluated in animals and in humans for 
potential toxicological effects. In rodents, the most prominent toxicities appear to be 
related to cytokine release induced by these drugs. In monkeys, complement 
activation, abnormalities in clotting, and hypotensive events have been reported, while 
in humans, doses of up  to 2mg/kg intravenously administered over 2 h have been 
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observed to be without significant toxicity (Crooke, 1996; Galbraith et al., 1994; Iversen, 
Copple and Tewary, 1995 ). Some of these effects were found to be dependent on 
ODN base sequence, backbone modification, and/or dosage schedule and could be 
avoided (Akhtar and Agrawal, 1997). However other authors sustain that insufficient 
purity is one of the main reasons for toxicity even of the otherwise properly designed 
oligos (Schlingensiepen and Schlingensiepen, 1997). 
 
1.7 Prospects for the future. 
 
Many diseases ultimately result from the production of a mutant protein or because the 
overproduction of a normal protein. The potential use of ODNs as therapeutical agents 
is attractive due to their theoretical specificity, relative ease of production and, to date, 
paucity of reported adverse effects. Embracing the idea that tomorrow's drugs will not 
merely treat symptoms, but also attack disease-causing genes, scores of  
biotechnology companies are developing compounds to intervene in the cell's genetic 
machinery in order to prevent the expression of specific genes involved in AIDS, 
cancer, and inflammatory disease, among other disorders (Sharma and Narayanan, 
1995; Mercola and Cohen, 1995; Metzger and Nyce, 1999; Monteith and Levin, 1999; 
Brysch and Schlingensiepen, 1994). 
The era of the oligos in the clinical environment seems to have already begun with the 
approval by the FDA of the first antisense oligonucleotide (Vitravene) for 
cytomegalovirus retinitis in AIDS patients as well as, with the proceeding of several 
clinical trials for certain inflammatory diseases and some cancers (Marcusson et al., 
1999; Yuen, Halsey and Fisher, 1999; Nemunaitis et al.,1999).  
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In the case of the CNS, the antisense technology  has been also established as an 
important neuropharmacological tool for targeting neurotransmitter receptors (Karle 
and Nielsen, 2000; Heilig, 1995; Zhang and Creese, 1993; Weiss et al., 1993), 
neuropeptides (Skutella et al., 1994a; Skutella et al., 1995; Jirikowski et al.,1995) and 
inducible transcription factors (Hooper, Chiasson and Robertson, 1994; 
Schlingensiepen and Heilig, 1997). For a possible use in the clinical environment on 
the CNS, neurooncology is the most intensively researched area at the moment 
(Tellería-Díaz, 2000), however, many obstacles still exist in the development and the 
immediate use of this technology as possible therapeutic option for certain 
neurological diseases. Delivery of ODNs to the CNS, toxicity problems with some 
oligos, and lack of information about the side effects that ODNs could induce within the 
brain upon repeated administration on the CNS are among the major problems. 
Therefore more investigations are required before a therapeutic applications of these 
molecules as treatment for certain neurological disorders seem feasible. For this goal, 
targeting certain neuropeptidergic system represents a very useful tool. 
 
1.8 The magnocellular neurons of the hypothalamo-neurohypophyseal system 
as standard model for the study of neuropeptidergic systems. 
 
For decades the magnocellular neurons of the hypothalamo-neurohypophyseal 
system (HNS), in which either vasopressin (VP) or oxytocin (OT) are produced, have 
been playing a pivotal role in fundamental discoveries in the nervous system. The 
magnocellular neurosecretory cells in the hypothalamus have been the most 
intensively studied peptidergic neurons in the nervous system since the primary 
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structure of VP and OT was the first of all neuropeptides to be published in the 1950s 
by the Nobel prize laureate Du Vigneaud (van Leeuwen et al., 1998). The HNS 
expresses abundantly and specifically these two neuropeptides, which clearly display 
their function and is relative ease of manipulation. In addition, isolation of perikarya, 
axons, and nerve terminals of these cells for anatomical, biochemical, and 
physiological analysis is also of relative easy (Gainer et al., 1995) as well, the 
assessment of the blood levels of OT and VP. 
 
1.9 The HNS. Anatomical and physiological remarks on the vasopressinergic 
system. 
 
The HNS consists of magnocellular neurons in which either the VP or OT precursor is 
synthesized, packaged and transported towards the terminals in the median eminence 
and the neural lobe of the pituitary, where the processed products (i.e., 
VP-neurophysin II and glycopeptide; OT-neurophysin I) are released into the 
bloodstream in response to certain stimuli. While the function of vasopressin is 
important for osmoregulation, OT regulates smooth muscle contractility in female and 
male reproductive tract, as well as milk ejection during lactation. 
VP and OT are nonapeptides that not only exert their actions as neurohypophysial 
hormones but also as important neurotransmitters or neuromodulators in different 
parts of the brain (Buijs, 1990).  VP is synthesized as a precursor prepropeptide, 
principally in magnocellular neurons whose cell bodies are located in the supraoptic 
nucleus (SON) and paraventricular nucleus (PVN) of the mammalian hypothalamus 
(Swanson and Sawchenko, 1983). The VP precursor is packaged into secretory 
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granules and is subject to cleavage and other modifications as it is transported from 
the cell bodies to storage in posterior pituitary nerve terminals (Brownstein, Russell 
and Gainer, 1980). The mature peptide products are the nonapeptide VP, a putative 
carrier molecule termed neurophysin (NP) and a 39 aminoacid glycopeptide 
(copeptin;CPP). These are stored in equimolar amounts in posterior pituitary terminals 
until neural inputs governed by physiological stimuli elicit their release (Renaud and 
Bourque, 1991). VP is a central component of the systems that regulate osmotic 
balance (Reeves and Andreoli, 1992). The physiological challenge of dehydration 
results in a rise in plasma osmolality that is detected by to date undefined 
osmoreceptor mechanisms. Subsequent excitation of the magnocellular hypothalamic 
neurons leads to a release of VP into the general circulation from posterior pituitary 
stores. VP travels through the blood stream to its ta rgets that exhibit specific receptors. 
Particularly, through an interaction with V2-type receptors located in the kidney, VP 
increases the permeability of the collecting ducts to water (Murphy et al., 1998). Thus, 
the hypothalamus (trough VP) promotes water conservation by decreasing the amount 
of water lost in the urine. The related nonapeptide hormone OT is also expressed in 
magnocellular neurons of the SON and PVN, but VP and OT are rarely found in the 
same cell under normal conditions (Vandesande and Dierickx, 1975).  
Immunohistochemical work from a number of laboratories has shown that both VP and 
OT neurons are present in each of the two principal hypothalamic magnocellular nuclei, 
the SON and PVN, and are not segregated into separate nuclei as some early studies 
had suggested. Nevertheless, it is now clear that there are  large numbers of VP and 
OT neurons in various locations outside of this classical localization, and that these 
neurons are heterogeneous in morphology and probably in function as well (Sofroniew, 
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1983) (Fig.4a and 4b). Such clusters of cells are usually referred to as accessory nuclei 
(Fischer et al., 1979) and in their composition there are  magnocellular and 
parvocellular neurons as well.  
 
Fig.4a and 4b. Distribution of main vasopressinergic and oxytocinergic cell groups and their 




In the rat brain was Peterson the first who described the majority of such nuclei more 
than 30 years ago, and termed as anterior commissural nucleus (ACN), fornical nuclei 
and the nucleus of the medial forebrain bundle (Peterson, 1966). Perhaps the most 
conspicuous of  the ”newly” identified locations is the suprachiasmatic nucleus (SCN), 
located bilaterally in the midline at the base of the third ventricle, just dorsal to the optic 
chiasm. In this nucleus, a portion of the neurons (parvocellular cells of 10-15µm in 
diameter) contain VP (but not OT) and its associated neurophysin (Sofroniew, 1983); 
this structure is currently being considered as the site of the master pacemaker 
controlling circadian rhythms (the neural or internal clock) and it has no connections 
with the posterior lobe (van Esseveldt, Lehman and Boer 2000; Ingram, 1998). Of 
particular interest are the studies showing that while osmotic perturbations increase 
the VP mRNA levels in the SON and PVN nuclei, the vasopressin neurons in the SCN 
do not increase their mRNA content under these conditions (Burbach et al., 1984). 
A large number of so called accessory magnocellular VP and OT neurons have been 
found also throughout the hypothalamus in different mammals including humans. As 
yet there is no accepted nomenclature for them, and there is considerable species 
variation regarding their precise location  (Sofroniew, 1983; Grinevich and Polenov, 
1994) . The best represented groups in different mammals are: (1) a group  in the 
dorsal anterior hypothalamus extending towards the stria terminalis; (2) diffuse cells 
and small groups in the anterior hypothalamus between the SON and PVN; (3) diffuse 
cells and small groups in the posterior hypothalamus; and (4) a group near the  fornix in 
the posterior hypothalamus. Many species have unique groups of such neurons. For 
example, one prominent group in the rat is the ACN, which is composed of OT neurons 
but is not present in most other mammals, including other rodents such as the guinea 
 18 
pig. The function of these dispersed groups is poorly understood. Neurons in different 
groups appear in some cases to have different projections. It also appears that 
different groups may be sensitive to different afferent stimuli (Sofroniew and  Schrell , 
1982). 
In addition to the previous, other neurons containing neurophysin and VP are located 
outside the hypothalamus. These include perikarya in the medial amygdala, in the bed 
nucleus of the stria terminalis (BST), and in the ventral lateral septum. These neurons 
are parvocellular and their immunostaining is far weaker than the one obtained for 
hypothalamic neurons but increases under colchicine treatment (Sofroniew, 1983). 
 
1.9.1 Morphological aspects of the SON and the PVN in the rat hypothalamus. 
 
The SON contains only magnocellular neurons and is divided into two parts, principal 
or anterior and retrochiasmatic or tuberal. The principal anterior division has been the 
subject of most experimental investigations. In the rat it begins with loosely packed 
neurons just dorsolateral to the optic chiasm as far rostral as the organum vasculosum 
of the lamina terminalis (OVLT) and extends caudally into the posterior hypothalamus 
as a dense cluster of deeply staining, large cells adjacent to the optic chiasm, and its 
most posterior aspect, ventrolateral to the ascending optic tract. The retrochiasmatic 
portion is a densely packed, thin sheet of cells close to the pial surface between the 
median eminence and the optic tract (Armstrong, 1995). 
The PVN consists of two parts with different functions. One contains parvocellular 
neurons which project to the median eminence, brain stem and spinal cord and may 
influence the regulation of anterior pituitary secretion and the autonomic nervous 
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system. The other part contains the magnocellular neurons, which project to the 
neurohypophysis (Bisset and Chowdrey, 1988). According to Swanson and Kuypers, 
the magnocellular division of the PVN in the rat can be viewed most simply as three 
dense clusters of magnocellular neurons embedded in a larger shell of parvocellular 
neurons that consists of five components. The anterior magnocellular part lies just 
ventromedial to the fornix at the level of the medial preoptic area; it corresponds for the 
most part to the ACN of Peterson. The medial magnocellular part consists of a small, 
compact group of large neurons in the periventricular and anterior parvocellular parts 
of the nucleus, between the anterior magnocellular part and the posterior 
magnocellular cell group, this medial magnocellular part may correspond to the 
posteromedial part of the ACN of Peterson. The large posterior magnocellular part 
corresponds to the magnocellular part of the PVN of most authors. It should be pointed 
out that the anterior part of the posterior magnocellular part contains a zone in which 
magnocellular and parvocellular neurons are intermixed (Swanson and Kuypers, 
1980). 
A clear immunocytochemical localization of the VP and OT-containing neurons has 
been observed in different parts of the SON and PVN in the rat. The anterior and the 
medial subnuclei of the magnocellular part  of the PVN consist almost exclusively of 
OT neurons. In the posterior subnucleus OT neurons are concentrated 
anteroventromedially and the VP neurons posterodorsolaterally (Swanson and 
Sawchenko, 1983). In the principal part of the SON OT neurons are concentrated 
anterodorsally and VP neurons posteroventrally; the majority of cells in the 
retrochiasmatic part contain VP (Rhodes, Morrell and Pfaff, 1981). 
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1.10 Aims of the present study. 
 
Since the magnocellular neurons of the rat hypothalamus represent an optimal model 
for the study of neuropeptidergic systems, the employment of an antisense 
oligonucleotide against the VP mRNA could provide us with profitable information 
about the effects of these compounds upon its application to the CNS. No studies on 
the repeated administration of a 19-base antisense molecule against the VP mRNA 
has been performed before. In the present study we evaluate the effect of an antisense 
oligonucleotide agains t such transcripts on the expression of VP, but also on the VP 











2. MATERIAL AND METHODS 
 
2.1 Animals and housing conditions. 
 
Intact adult Wistar male rats (n=16) weighing 250 to 300 g served as experimental 
subjects. Animals were initially in plastic cages on a 12 hour dark, 12 hour light cycle 
with free access to standard lab chow and water. Twelve hours before oligo 
administration, rodents were placed individually in metabolic cages to measure water 




For intracerebroventricular (i.c.v.) injections, a chronic polyethylene cannula (PP 20; 
LHD Heidelberg) was implanted under chloralhydrate anesthesia (400 mg/kg BW, 
intraperitoneally) into the left lateral ventricle 7 to 9 days before the experiment. The 
stereotaxic coordinates were took from a stereotaxic atlas (Paxinos and Watson, 1982) 
and they were: 1.3 mm lateral to the midline, 0.6 mm posterior to the bregma and 5 mm 
vertical from the skull surface. Five or seven days after surgery, angiotensin II (25 pmol) 
was injected i.c.v. to each rat. Only those animal which responded with an immediate 
drinking were included in further experiments. The animals were anesthetized again, 
and a polyethylene catheter (PP 50, HDL, Heidelberg, Germany) filled with heparinized 
saline was inserted in the femoral vein through a subcutaneous tunnel, sealed and 
secured at the back of the neck.  
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The correct position of the i.c.v. cannulae was verified histologically by postmortem 
dissection at the end of the experiment. 
 
2.3 Antisense oligo.  
 
On the basis of the sequence of VP cDNA, we  designed a  19-base 5’-3’  end capped 
phosphorothioate antisense ODN that corresponded to the beginning of the initiation 
codon of the VP mRNA (5’-CAT GGC GAG CAT AGG TGG A-3’). Synthesis was 
performed at the Institut für Molekulare Biotechnologie, Jena, by Dr. Birch Hirschfeld. 
ODNs were purified by gelfiltration and HPLC. Mismatch ODN bases and saline 
solution were used as controls. Both the antisense and the mismatch constructs were 
compared to the GenBank database (Entrez) and found to have little or no homology to 
mRNAs registered in GenBank. 
 
2.4 Intracerebroventricular infusions. 
 
Animals were handled and sham injected frequently so that actual i.c.v injections and 
blood withdrawal could be performed without anesthesia. ODNs  or vehicle were slowly 
infused i.c.v. using a Hamilton syringe connected to a 25-gauge injection needle via 
polyethylene tubing. ODNs were administered slowly over a 120 seconds period, with 
the injection needle left in the i.c.v. cannula for 3 to 4 min to ensure complete injection 
of the ODNs.  
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Animals received two i.c.v. injections at 4-hour intervals of either antisense oligo [n=5], 
mismatch oligo [n=5] (15 µg of each) or saline[n=6]. The first i.c.v injection was given 
between 2:00 and 3.00 pm, and the second one between 6:00 and 7.00 pm. 
ODNs were dissolved in sterile saline solution (0.9% NaCl) and injected at a dose 15 
µg/1.5 µL (1.5 µL flushed with 5 µL of saline). 
 
2.5 Water consumption and urine osmolality assessment. 
 
Water intake was determined by weighing of water which the rat drank during a 
12-hour time period (from 6.00 pm to 6.00 am). Urine osmola lity was measured at the 
beginning and at the end of the experiment with an osmometer.   
 
2.6 Blood collection for vasopressin determination in plasma. 
 
Blood sampling was carried out in conscious and unrestrained rats 12 h after the last 
i.c.v vehicle or ODN injection. The grid cage tops were removed and the femoral vein 
catheter was connected to an extension catheter (PP 50) with a syringe, both filled with 
heparinized saline. The rats were allowed to adapt to the new environment (open cage) 
for at least 30 min. Blood (1 ml) was slowly withdrawn from the femoral vein catheter in 
ice-cold heparinized Eppendorf tubes. Blood samples were centrifuged at 3,000 x g in 
a refrigerated centrifuge, plasma was removed and stored at –75°C until assayed for 
AVP content. VP radioimmunoassays were performed in the routine laboratory of the 





After the blood sampling, animals were killed by prolonged ether anesthesia, followed 
by cardiac perfusion with 4% paraformaldehyde in PBS. Brains were removed and 
postfixed in the same fixative over night. Serial frontal sections (100µm) were cut on a 
vibratome and collected in PBS. Pituitaries were dehydrated in ascending series of 
ethanol and embedded in EPON. Serial semithin sections (0.5µm) were cut on a 
Reichert Ultracut microtome and affixed onto glass slides. Epoxy resin was removed 
with sodium methoxide, for details see (Jirikowski et al., 1990).  Floating vibratome 
sections were incubated overnight at 4°C with rabbit anti VP (Chemicon) diluted 
1:1000 in PBS containing 0.05% Triton X-100.  
After incubation with anti-rabbit IgG (Sigma) diluted 1:100 in PBS for 30 min at room 
temperature, sections were incubated with rabbit peroxidase-antiperoxidase (Sigma) 
diluted 1:100 in PBS for 30 min at room temperature. Immunoprecipitates were stained 
with 3´, 3´-diaminobenzidine and H2O2. Some of the sections were mounted in PBS for 
brief microscopical evaluation. Thereafter immunocomplexes were removed by 
incubating the sections in HCL (1mN) for 15 minutes, followed by washing in PBS 1X 
15min. Sections were incubated overnight at 4°C with Anti-OT (Chemicon) diluted 
1:500 in PBS containing 0.05% Triton X-100. Subsequently sections were rinsed in 
PBS 1X10min and incubated for 2 hours at room temperature with CY3-labeled anti 
rabbit IgG (Jackson Immuno Research Laboratories, Inc.) diluted 1:200. After washing 
in PBS (3X10 min) sections were affixed onto slides, coverslipped with Moviol (Sigma) 
and evaluated with  epifluorescence or phase contrast ilumination with an Olympus 
photomicroscope.  
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2.7 Statistical analysis. 
 
Counting of cells was performed in  supraoptic (SON) and paraventricular (PVN) nuclei. 
For standardization, we selected sections at identical planes [~ interaural 7.70 mm, 
Bregma-1.30 mm for SON, and interaural 7.20 mm, Bregma-1.80 mm for PVN] for 
quantification (Fig.5 and Fig.6). VP and OT cell populations were determined by 
counting the total number of immunoreactive neurons (soma). 
The data from the water intake and the blood levels of VP were analyzed (mean, SD, 
SEM) using the a statistical software package (SPSS 10.0 for windows). The results 
are presented as mean and SEM. In order to compare two means, the Mann-Whitney 





















Fig.5 and 6. SO: Supraoptic nucleus, PaV: Paraventricular nucleus with the PaVP (parvocellular) and 
PaLM (magnocellular) components (Paxinos and Watson, 1997). 
 
 


























































































































3.1 Water consumption and urine osmolality. 
 
Rats injected with the antisense and mismatch oligo showed within 2h of the first 
injection reduced drinking behavior in comparison to the saline injected control animals. 
Total water consumption was determined at the end of the experiment. Animals 
injected with the antisense oligo showed significantly reduced water intake as 
compared with saline controls (p<0,05). Water intake was also reduced in comparison 
to animals injected with the mismatch oligo but this difference was not significant  
(Fig.7). Symptoms of diabetes insipidus were not observed in the experimental group.   
 
3.2 Vasopressin blood levels. 
 
Immunoassays of serum, from the blood collected trough the femoral catheter  at the 
end of the experiment showed increased vasopressin levels in the antisense group 
compared to saline (p=0,05 ) and mismatch (p=0,15) treated animals, but this however 





















































Fig.7: Water consumption(ml/12h) 




3.3.1 Vasopressin immunostaining. 
 
Neurons immunostained with Anti-VP could be visualized in the hypothalamus of all 
animals in the SON including in its retrochiasmatic portion, the magnocellular and the 
parvocellular PVN, suprachiasmatic nucleus (SCN) and also in various regions outside 
of the classical magnocellular nuclei, e.g, in the intersupraoptic-paraventricular islands 
(ispi). Scattered VP neurons were also seen in the BST, medial preoptic area (mpoa), 
perifornical region (pf), in the ansa lenticularis (AL) and the zona incerta (Zi) and 
occasionally in the periventricular nucleus (Pe) of some animals in all groups. 
Antisense treated animals appeared to have a similar distribution of vasopressin 
immunoreactive perikarya in the SON and the PVN as the controls. VP 
immunostaining was also present in bundles of nerve fibers in the median eminence 
and in the posterior lobe. No VP neurons were seen in the medial amygdala of any 
group. In the antisense group, the overall intensity of VP staining in magnocellular 
neurons and Herring bodies appeared to be similar to the intensity observed in control 
groups (Figs 9A, 10A and 10E). 
 
3.3.2 Oxytocin immunofluorescence and colocalization of VP and OT. 
 
OT immunofluorescence was mostly seen in perikarya and processes of 
magnocellular neurons from the SON, PVN, the lateral subcommissural nucleus (LSN) 
(LSN=ACN) and in varicosities of the median eminence. Few cells from the Pe nucleus 
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and perivascular groups also showed OT immunofluorescence. The number of 
neurons that showed OT immunoreactivity were usually much higher in the SON and 
PVN of the antisense treated group (Fig. 10B, 10D) as compared with control animals 
(Figs 9B, 10F). OT immunofluorescence was also observed in many of the 
magnocellular neurons that stained also for VP (Figs 10A, 10B, 10C, 10D). In the SON 
of antisense injected animals coexistence of both peptides was found in about 30% of 
the neurons, while in the magnocellular portion of the  PVN colocalization was evident 
in more than 40% of these cells. Coexistence of both immunoreactivities was seldom 
observed in few and scattered neurons in saline- or mismatch probe injected controls. 
Double staining for VP and OT was observed occasionally in scattered cells in the 
antisense injected rats in the ispi, BST, mpoa, pf, AL, Pe and Zi. The parvocellular 
portion of the PVN and the SCN contained only VP positive neurons in all experimental 
groups, LSN was only oxytocinergic in all animals examined.  
 
3.3.3 VP and OT in the posterior lobe. 
 
Some of the neurosecretory terminals in the posterior lobe contained both 
immunoreactive peptides in the animals treated with the antisense oligo. Comparison 
of consecutive semithin sections of the posterior pituitary lobe also revealed 
coexistence of VP and OT in a fraction of the Herring bodies in these animals (Figs 11A, 
11B). In both controls we observed OT and VP immunostaining in distinct populations 
of nerve terminals and Herring bodies (Figs 11C, 11D).  
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Fig 9: Control animals showed distinct patterns for VP immunostaining in the SON (Fig. 
9A), with no coexistence for OT, as visible by immunofluorescence (Fig. 9B), neurons 
containing OT did not stain for VP (Fig. 9B. arrows). Similar observations could be 
made for the PVN (Fig. 9C for VP and Fig 9D for OT). There was not immunostaining 
for OT in the SCN, emphasizing specificity of the methods employed (Fig. 9E-F). 
Fig. 9
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Fig 10: SON of a rat treated with the antisense oligo. VP immunostaining (Fig. 10A) 
corresponds to a large extent with OT immunofluorescence (Fig. 10B. arrows). Similar 
phenomena was also observed in the PVN (Figs. 10C and 10D). SON of a control 
animal (Mismatch probe) showed distinct pattern for VP immunostaining (Fig. 10E) 
and OT immunofluorescence (Fig. 10F). The number of perikarya with OT 




Fig 11: Consecutive semithin sections of the posterior lobe, immunostained for VP 
(Figs.11A and 11C) and OT (Fig.11B and 11D). Coexistence of both 
immunoreactivities is observable in a fraction of the Herring bodies in the antisense 
treated group (Figs. 11A and 11B. Arrows), however, such phenomena of 
colocalization was not detected in all terminals (Figs. 11A and 11B. Asterisk). Control 





4.1.  Behavioral effects of  antisense targeting on VP mRNA expression. 
 
VP is a central component of the systems that regulate osmotic balance. Particularly, 
through an interaction with V2-type receptors located in the kidney, VP increases the 
permeability of the collecting ducts to water. However, little is known about the 
mechanisms that regula te VP gene expression, in terms of either the synaptic 
regulation, physiological status, or the downstream second messenger and 
transcription factor systems involved (Murphy et al., 1998). 
In vivo antisense targeting with synthetic oligonucleotide probes has evolved as a 
useful tool to block neuropeptide expression on the translational level. In the present 
study we injected intracerebroventricularly a 19-mer phosphorothioate modified 
antisense oligonucleotide, which corresponded to the beginning of the initiation codon 
of the arginine vasopressin precursor. Single pulse injections of 50µg or more of this 
oligonucleotide have been shown to induce a transitory diabetes insipidus (DI) in rats 
(Skutella et al., 1994b). Meeker et al. (1995) found a decrease in AVP mRNA and a 
compensatory drinking response within the first 24 h upon the administration of an 
antisense AVP oligonucleotide. Here we injected only 15µg of this probe twice, and DI 
was not observed in any of our experimental animals, probably due to the lower dose. 
Unexpectedly we also observed a reduction of water intake in the animals who 
received antisense, but also in those who received mismatch oligonucleotides, 
therefore this finding can not be considered as an specific effect of such oligo, not even 
when the decrease on water consumption was higher in the antisense treated group. 
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This idea is also reinforced by the lack  of a significant increase in the blood levels of 
VP in the antisense treated animals.  
 
4.2. The phenomena of VP and OT colocalization in the HNS. 
 
 
Most of the magnocellular neurons of the rat hypothalamo neurohypophysial system 
contain in intact rodents both vasopressin and oxytocin encoding transcripts as 
determined by single cell RT-PCR (Xi et al., 1999). Nevertheless 
immunocytochemistry and in situ hybridization fails to detect coexistence of both 
nonapeptides in most cells in intact animals (Mohr et al. 1993a), indicating that the 
coexpression of OT and VP neuropeptides does not occur under normal conditions 
and thus suggesting that the  translation of OT mRNA may be repressed in 
VP-expressing neurons and vice versa  in unchallenged animals.  
Physiological challenge of oxytocinergic neurons occurs during parturition, resulting in 
a coexistence of both peptides in 20% of the magnocellular neurons (Jirikowski et al. 
1991) and in 17% in lactating animals (Mezey and Kiss, 1991).  Although the molecular 
mechanisms involved in the coexistence of OT and VP observed in such studies are 
not yet clear, it  could be assumed that an increase in the VP translation during these 
situations could represent  an essential mechanism to maintain the homeostasis, since 
VP could be required for maintaining blood pressure during the hemorrhage 
associated with parturition, or to retain water as compensatory mechanism due to a 
loss of fluid during lactation  (Jirikowski et al. 1991; Mezey and Kiss, 1991). Another 
possible explanation could be also that, current VP neurons were recruited in to OT 
production  as additional source for OT during lactation and parturition, perhaps as 
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consequence of receiving the same stimulus that elicit OT production from 
oxytocinergic neurons during these situations. 
Stimulation of vasopressinergic neurons by osmotic stress through water deprivation 
also induces coexistence of both peptides in a certain numbrer of cells in the 
magnocellular population of  the SON and the PVN (Telleria Diaz et al., 2001). The 
question whether OT neurons are recruited into VP expression upon prolonged 
osmotic challenge, to compensate the deficit of VP, VP neurons start to express OT or 
whether dormant populations of magnocellular neurons are activated to synthesize 
both neuropeptides is difficult to establish with this experiment. The role of OT in the 
regulation of water balance has been postulated since several years (Han et al., 1992). 
Previous and recent reports suggest that OT is able to bind VP V2 receptor (V2R) in 
kidney, thus stimulating levels of aquaporin 2, to cause antidiuresis. The activation of 
V2R by OT could partially compensate water conservation, however the affinity of OT 
for V2R is lower than VP (Terashima et al., 1999), so the role of this nonapeptide for 
osmoregulation seems to be less prominent than the are exerted by VP. Nevertheless, 
the observed coexistence of VP and OT immunoreactive peptides in the HNS, which in 
part seems to be reversible, is another example for the highly specific functional  
plasticity of the magnocellular hypothalamic system in response to special demands or 
during conditions of strong stimulation (Telleria Diaz et al., 2001). 
Osmotic stimuli such as dehydration or salt-loading resulted in an increase in VP gene 
transcription (Murphy and Carter, 1990; Herman et al., 1991), a concomitant increase 
in VP mRNA abundance (Burbach et al., 1984; Zingg et al., 1986; Lightman and Young, 
1987; Sherman et al., 1988) and an increase in the lenght of VP RNA poly (A) tail 
(Carrazana et al., 1988;. Carter and Murphy, 1989). OT gene has also shown similar 
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regulation by osmotic stimuli (Lightman and Young, 1987; Van Tol et al., 1987). 
Apparently the neuroendocrine cells in the hypothalamo neurohypophysial system are 
to a great extent malleable to functional changes, even to the extent that unrelated 
peptides are synthesized. These assumptions seem only to be true for peptidergic 
neurons that contribute to the posterior lobe and infundibular system. Centrally 
projecting neurons like the OT neurons in the LSN or the parvocellular VP cells in the 
PVN and the SCN did not show VP and OT coexpression under the experimental 
conditions, despite the fact that the neurons from the LCN are known to be 
osmosensitive (Grinevich and Akmayev, 1997). 
The phenomena of VP and OT colocalization in a certain fraction of magnocellular 
neurons in the antisense treated group could respond to an increase in the VP mRNA 
transcription following and initial depletion in the levels of VP mRNA due perhaps to a 
RNase-H mediated mechanism. Maybe this lower dose of the antisense oligo initially 
decreased the amount of VP transcripts, which could be quickly followed by a 
compensatory increase of the VP mRNA and VP by means of de novo-transcription 
and translation, and thus avoiding the development of a DI in these animals. The lower 
or the remnant amount of the antisense oligo could be then insufficient to inactivate all 
of the new VP transcripts. However in this case, it should then be keep in mind that 
colocalization of both peptides should be also found in the ACN, which did not happen 
in our study group . Although the OT magnocellular neurons from the ACN have been 
considered by some authors the most anterior portion of the PVN (Swanson and 
Kuypers, 1980), these cells do not project to the posterior lobe, but to the median 
eminence. According to the evidence of some investigations (Arai et al, 1996; Fenelon 
et al, 1993; Laurent et al, 1989; Chernigovskaia et al 1985), it is very likely this group of 
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cell is a completely different structure from the PVN and therefore, the lacking of 
coexpression of VP and OT in the antisense treated animals could be explained by this 
functional differentiation. 
Another possibility to rule out is the triple helix formation, since these structures could 
upregulate the expression of a gene (Imagawa et al., 1994). Triple helices can be both 
intra- and intermolecular in character (Gfrörer et al. 1993). In classical triple helices or 
intermolecular triplexes, the duplex involved in triplex formation must have a 
homopurine sequence  in one strand (adenine or guanine), attending these are the 
nitrogen bases which offer additional junction sites for a third strand by means of 
Hydrogen bonds (TS´O POP et al. 1992).  However in our case, neither the selected 
target sequence nor the designed oligo presented this feature. Therefore the possibility 
for triple helix formation in our antisense treated group is rather unlikely.  
There is also a theoretical possibility of the antisense ODN binding to the locally 
opened loop created by RNA polymerase (Phillips and  Gyurko, 1997). An opened loop 
could result in increased accessibility of binding sites for transcription factors and thus 
stimulate transcription of another genes. This possibility should be considered, since 
the coding genes for VP and OT they are located on the same chromosomal locus very 
close each other, only separated by 11KB but oriented in opposite transcriptional 
directions (Mohr et al., 1988b; Richter, 1988; Gainer and Wray, 1992). Therefore OT 
gene could be activated, resulting in the expression of the OT in a certain number of 
vasopressinergic cells, thus resulting in the colocalization of VP and OT observed in 
the antisense treated group. The lower dose of the employed oligo may not be enough 
to produce a translational arrest of the VP gene, sufficient to decrease VP production, 
but enough to increase the transcription of the OT gene through the mechanism 
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mentioned above. As a consequence a translational activation of OT is very likely. OT 
peptide would be stored in the soma of the magnocellular neurons since at the moment 
of the experiment there was not a real peripheral demand for the release of OT.  
Another possibility to be considered is the production of a paradoxical effect. Such 
effects of ODN treatment have been encountered even in the most simple in vitro 
systems (Engelhard, http://www.moffitt.usf.edu /cancjrnl/v5n2/article7.html, Williard et 
al., 1994), and the mechanisms of these nonspecific effects of ODNs could be related 
to (1) the structure of the ODN itself, (2) hybridization to DNA or mRNA other than the 
target sequence, with subsequent RNase cleavage, (3) binding to proteins or other 
molecules, and/or (4) ODN degradation products, which in themselves can affect 
cellular functions.( Hélène, 1994; Altmann et al., 1996, Milligan et al., 1993; Ma and 
Calvo, 1996; Wagner, 1994; Warzocha, 1997; Carter and  Lemoine, 1993; Mahon et al, 
1995; Weidner and  Busch 1994). However this possibility seems to be very unlikely 
here, since a previous study has shown that  this oligo with higher dose indeed induced 




 In a previous study, the i.c.v administration of higher dose of this oligo probe against 
the initiation codon of VP was shown to produce DI in rats (Skutella et al., 1994b). In 
the present work, the double i.c.v  injection of a lower dose of such p robe did not affect 
the blood levels of VP, neither produced DI in the experimental group, but on the other 
hand, it seems that, the OT production was either upregulated in vasopressinergic 
magnocellular neurons or that, oxytocinergic cells started to produce VP, leading to the 
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coexpression of both peptides in a fraction of the magnocellular neurons in the HNS of 
these animals. With the available data is difficult to establish the origin and the actual 
underlying mechanism of this phenomenon of colocalization, however, this finding 
could be another evidence that the administration of an antisense oligo against certain 
proteins can modify the expression of a different gene than the one that was targeted. 
The overproduction of another protein could perhaps also explain some of the side 
effects observed in some experiments upon the administration of antisense probes. 
Therefore, before considering this technology as the ”Magic Bullet” and introducing 
any of these substances for clinical use, it should be ruled out in each experimental 
animal setting whether or not the oligo under investigation affect the expression of 




In vivo antisense Targeting mit synthetischen Oligonukleotid- Sonden, die 
komplementär zu spezifischen neuropeptidergen Transcripten sind, wird als 
Alternative zu transgenen Tiermodellen bei bestimmten Fragestellungen diskutiert. Die 
Technik des Antisense Targetings hat auch große Erwartungen hinsichtlich einer 
möglichen neuropharmakologischen Anwendung geweckt. Die tatsächlichen 
molekularen und zellulären  Abläufe, die dieser Technik zugrunde liegen sind aber bis 
heute noch weitgehend unbekannt. In der vorliegenden Arbeit injizierten wir in Ratten 
intracerebroventrikulär eine synthetische Oligonukleotid-Sonde, die komplementär zur 
Startcodon Region des Arginin-Vasopressin Precursors war. Hochdosierte 
Einzelinjektionen dieser Sonde induzierten in Ratten vorübergehend Diabetes 
insipidus. Bei zwei aufeinanderfolgenden Injektionen von geringen Dosen der 
Oligonukleotid-Sonde wurden die Plasma-Vasopressin-Spiegel aber nicht verändert, 
die Wasseraufnahme dieser Tiere war sogar leicht reduziert. Mit Immunzytochemie 
beobachteten wir in den magnozellulären hypothalamischen Kerngebieten und im 
Hypophysen-Hinterlappen eine Koexistenz von Vasopressin und Oxytocin. Obwohl die 
tatsächlichen Ursachen der Koexpression dieser beiden hypothalamsichen 
Peptidhormone schwer zu bestimmen sind liegt der Schluß nahe, daß 
Oligonukleotid-Sonden direkt oder indirekt in der Lage sind, auch die Expression 
anderer als der eigentlich vorgesehenen Gene zu modulieren. Dieser Gesichtspunkt 
sollte bei einer möglichen späteren therapeutischen Anwendung von in vivo 





In vivo antisense targeting with synthetic oligonucleotides complementary to specific 
neuropeptidergic transcripts has been proposed as a tool to replace transgenic animal 
models for certain experimental settings, thus having potentially great 
neuropharmacological implications. The actual molecular and cellular events 
associated with this approach however are mostly unknown to date. In the present 
study we injected intracerebroventricularly a synthetic oligonucleotide, complementary 
to the startcoding region of the Arg-vasopressin precursor. Single pulse injections of 
high doses of this oligo have been shown to induce a transitory diabetes insipidus in 
rats. Here we injected twice lower doses of this oligonucleotide which did not affect the 
plasma vasopressin levels and resulted in a non significant reduction of water intake. 
With immunocytochemistry we observed a coexistence of vasopressin and oxytocin in 
the magnocellular hypothalamic nuclei and in the posterior lobe. The underlying 
mechanism of such coexpression is difficult to establish here, however we can 
conclude that the employment of these compounds can modify the expression of a 
different  gene than the targeted, which should be keep in mind for the use of this 




Agrawal S, Temsamani J, Tang JY (1991) Pharmacokinetics, biodistribution, and 
stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A 
88(17):7595-9. 
 
Akhtar S, Agrawal S (1997) In vivo studies with antisense oligonucleotides. Trends 
Pharmacol Sci 18(1):12-8. 
 
Akhtar S, Basu S, Wickstrom E, Juliano RL (1991) Interactions of antisense DNA 
oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res 
19(20):5551-9. 
 
Akhtar S, Juliano RL (1992) Cellular uptake and intracellular fate of antisense 
oligonucleotides. Trends Cell Biol  2: 139-144. 
 
Altmann KH, Fabbro D, Dean NM, et al (1996) Second-generation antisense 
oligonucleotides: structure-activity relationships and the design of improved 
signal-transduction inhibitors. Biochem Soc Trans 24:630-637. 
 
Arai R, Jacobowitz DM, Nagatsu I (1996) Calretinin is differentially localized in 
magnocellular oxytocin neurons of the rat hypothalamus. A double-labeling 
immunofluorescence study. Brain Res 735(1):154-8 
 
 47 
Armstrong WE (1995) Morphological and electrophysiological classification of 
hypothalamic supraoptic neurons. Prog Neurobiol  47(4-5):291-339. 
 
Bisset GW, Chowdrey HS (1988) Control of release of vasopressin by neuroendocrine 
reflexes. Q J Exp Physiol  73(6):811-72. 
 
Boiziau C, Kurfurst R, Cazenave C, Roig V, Thuong NT, Toulme JJ (1991) Inhibition of 
translation initiation by antisense oligonucleotides via an RNase-H independent 
mechanism. Nucleic Acids Res  19(5):1113-9. 
 
Brownstein MJ, Russell JT, Gainer H (1980) Synthesis, transport, and release of 
posterior pituitary hormones. Science  207(4429):373-8. 
 
Brysch W, Magal E, Louis JC, Kunst M, Klinger I, Schlingensiepen R, Schlingensiepen 
KH (1994) Inhibition of p185c-erbB-2 proto-oncogene expression by antisense 
oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and 
strongly inhibits mammary tumor-cell proliferation. Cancer Gene Ther 1(2):99-105. 
 
Brysch W, Schlingensiepen KH (1994)  Design and application of antisense 
oligonucleotides in cell culture, in vivo, and as therapeutic agents. Cell Mol Neurobiol  
14(5):557-68. 
 
Buijs RM (1990) Vasopressin and oxytocin localization and putative functions in the 
brain. Acta Neurochir Suppl (Wien)  47:86-9. 
 48 
 
Burbach JP, De Hoop MJ, Schmale H, Richter D, De Kloet ER, Ten Haaf JA, De Wied 
D (1984) Differential responses to osmotic stress of vasopressin-neurophysin mRNA 
in hypothalamic nuclei. Neuroendocrinology  39(6):582-4. 
 
Burbach JP, De Hoop MJ, Schmale H, Richter D, De Kloet ER, Ten Haaf JA, De Wied 
D (1984) Differential responses to osmotic stress of vasopressin-neurophysin mRNA 
in hypothalamic nuclei. Neuroendocrinology  39(6):582-4. 
 
Carrazana EJ, Pasieka KB, Majzoub JA (1988) The vasopressin mRNA poly(A) tract is 
unusually long and increases during stimulation of vasopressin gene expression in 
vivo. Mol Cell Biol 8(6):2267-74. 
 
Carter DA, Murphy D (1989)  Independent regulation of neuropeptide mRNA level and 
poly(A) tail length. J Biol Chem  264(12):6601-3. 
 
Carter G, Lemoine NR (1993) Antisense technology for cancer therapy: does it make 
sense? Br J Cancer  67:869-876. 
 
Chen TL, Miller PS, Ts'o PO, Colvin OM, Chem TL (1991) Disposition and metabolism 
of oligodeoxynucleoside methylphosphonate following a single i.v. injection in mice. 




Chernigovskaia EV, Belen'kii MA, Danilova OA (1985) Ultrastructure of the 
neurosecretory cells of the anterior commissural nucleus of the hypothalamus in rats. 
Tsitologiia 27(3):345-7. 
 
Crooke ST (1996 )  Progress in antisense therapeutics. Med Res Rev 16(4):319-44. 
 
Crooke ST (1993) Progress toward oligonucleotide therapeutics: pharmacodynamic 
properties. FASEB J 7(6):533-9. 
 
Dagle JM, Weeks DL, Walder JA (1991) Pathways of degradation and mechanism of 
action of antisense oligonucleotides in Xenopus laevis embryos. Antisense Res Dev 
1(1):11-20. 
 
Engelhard HH. Antisense Oligodeoxynucleotide  Technology: Potential Use for the 
Treatment of Malignant Brain Tumors. http://www.moffitt.usf.edu 
/cancjrnl/v5n2/article7.html. 
 
Fenelon VS, Poulain DA, Theodosis DT (1993) Oxytocin neuron activation and Fos 
expression: a quantitative immunocytochemical analysis of the effect of lactation, 
parturition, osmotic and cardiovascular stimulation. Neuroscience 53(1):77-89 
 
Fisher AW, Price PG, Burford GD, Lederis K (1979) A 3-dimensional reconstruction of 
the hypothalamo-neurohypophysial system of the rat. The neurons projecting to the 
 50 
neuro/intermediate lobe and those containing vasopressin and somatostatin. Cell 
Tissue Res 204(3):343-54. 
 
Gainer H, Jeong SW, Witt DM, Chin H (1995) Strategies for cell biological studies in 
oxitocinergic neurons. In: Ivell R, Rusell J, ed. Oxytocin. Plenum Press New York; 
p.1-8. 
 
Gainer H, Wray S (1992) Oxytocin and vasopressin. From genes to peptides. Ann N Y 
Acad Sci 652:14-28 
 
Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S (1994)  Complement 
activation and hemodynamic changes following intravenous administration of 
phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4(3):201-6. 
 
Galderisi U, Cascino A, Giordano A (1999)  Antisense oligonucleotides as therapeutic 
agents. J Cell Physiol 181(2):251-7. 
 
Gfrörer A, Schnetter ME, Wolfrum J, Greulich KO (1993) Double and triple helices of 
Nucleic acid polymers, studied by uv-resonance raman spectroscopy.  Ber Bunsenges 
Phys Chem  97(2): 155-62. 
 
Grinevich V, Akmayev IG (1997)  An accessory magnocellular nucleus, anterior 
commissural nucleus, in the rat hypothalamus: immunohistochemical, tract-tracing, in 
situ hybridization, and experimental studies. Biogenic Amines 13: 333-48. 
 51 
 
Grinevich VV, Polenov AL (1994) The evolution of the nonapeptidergic neurosecretory 
formations of the hypothalamus in vertebrate animals. Zh Evol Biokhim Fiziol 
30(2):270-92. 
 
Han ZS, Duan XQ, Ju G (1992)  Neuronal responses of the anterior commissural 
nucleus to osmotic stimulation and angiotensin II in hypothalamic slices in the rat. 
Neurosci. Lett 144: 90-94. 
 
Heilig M, Schlingensiepen R (1996) Antisense oligodeoxynucleotides as novel 
neuropharmacological tools for selective expression blockade in the brain. In: 
D.S.Latchman, ed. Genetic manipulation of the nervous system. Academic Press 
London; p.249-68. 
 
Heilig M (1995)  Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression 
blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases 
feeding. Regul Pept 59(2):201-5. 
 
Hélène C (1994) Control of oncogene expression by antisense nucleic acids. Eur J 
Cancer. 30A:1721-1726.  
 
Herman JP, Schafer MK, Watson SJ, Sherman TG (1991) In situ hybridization analysis 




Hooper ML, Chiasson BJ, Robertson HA (1994)  Infusion into the brain of an antisense 
oligonucleotide to the immediate-early gene c-fos supresses production of fos and 
produces a behavioral effect. Neuroscience 63(4):917-24. 
 
Imagawa S, Izumi T, Miura Y (1994) Positive and negative regulation of the 
erythropoietin gene. J Biol Chem 269(12):9038-44. 
 
Inagaki M, Togawa K, Carr BI, Ghosh K, Cohen JS (1992) Antisense oligonucleotides: 
inhibition of liver cell proliferation and in vivo disposition. Transplant Proc 24(6):2971-2. 
 
Ingram CD, Ciobanu R, Coculescu IL, Tanasescu R, Coculescu M, Mihai R (1998) 
Vasopressin neurotransmission and the control of circadian rhythms in the 
suprachiasmatic nucleus. Prog Brain Res 119:351-64. 
 
Iversen PL, Copple BL, Tewary HK (1995) Pharmacology and toxicology of 
phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicol Lett 
82-83:425-30. 
 
Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, 
Schlingensiepen KH, Brysch W (1993) The effect of transforming growth factor-beta 
2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular 
immunosuppression in malignant glioma. J Neurosurg 78(6):944-51. 
 
 53 
Jirikowski GF, Celeda D, Jantz M, Prufer K, Lee JS (1995)  Sense- and 
antisense-targeting of oxytocinergic systems in the rat hypothalamus. Adv Exp Med 
Biol 395:59-65. 
 
Jirikowski GF, Ramalho-Ortigao FJ, Caldwell JD (1991) Transitory coexistence of 
oxytocin and vasopressin in the hypothalamo neurohypophysial system of parturient 
rats. Horm Metab Res 23(10):476-80. 
 
Jirikowski GF, Ramalho-Ortigao JF, Kesse KW, Bloom FE (1990) In situ hybridization 
of semithin Epon sections with BrdU labelled oligonucleotide probes. Histochemistry 
94(2):187-90 
 
Karle J, Nielsen M (2000) Targeting brain GABAA receptors with antisense 
oligonucleotides: implications for epilepsy. Methods Enzymol  314:20-32. 
 
Kulka M, Smith CC, Aurelian L, Fishelevich R, Meade K, Miller P, Ts'o PO (1989) Site 
specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s 
complementary to the acceptor splice junction of herpes simplex virus type 1 
immediate early mRNA 4. Proc Natl Acad Sci U S A 86(18):6868-72. 
Laurent FM, Hindelang C, Klein MJ, Stoeckel ME, Felix JM (1989) Expression of the 
oxytocin and vasopressin genes in the rat hypothalamus during development: an in 
situ hybridization study. Brain Res Dev Brain Res 46(1):145-54 
 
 54 
Lemaitre M, Bayard B, Lebleu B (1987) Specific antiviral activity of a 
poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to 
vesicular stomatitis virus N protein mRNA initiation site. Proc Natl Acad Sci U S A 
84(3):648-52. 
 
Lightman SL, Young WS 3rd (1994) Vasopressin, oxytocin, dynorphin, enkephalin and 
corticotrophin-releasing factor mRNA stimulation in the rat. J Physiol 1987;394:23-39. 
Ma DD, Doan TL. Antisense oligonucleotide therapies: are they the "magic bullets"? 
Ann Intern Med 120(2):161-3. 
 
Ma L, Calvo F (1996) Recent status of the antisense oligonucleotide approaches in 
oncology. Fundam Clin Pharmacol. 10:97-115. 
 
Mahon FX, Ripoche J, Pigeonnier V, et al (1995) Inhibition of chronic myelogenous 
leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides 
targeted at the B2A2 junction. Exp Hematol 23:1606-1611. 
 
Manche L, Green SR, Schmedt C, Mathews MB (1992) Interactions between 
double-stranded RNA regulators and the protein kinase DAI. Mol Cell Biol 
12(11):5238-48. 
 
Mercola D, Cohen JS. Antisense approaches to cancer gene therapy. Cancer Gene 
Ther 1995; 2(1):47-59. 
 
 55 
Metzger WJ, Nyce JW (1999) Oligonucleotide therapy of allergic asthma. J Allergy Clin 
Immunol  104(2 Pt 1):260-6. 
 
Mezey E, Kiss JZ (1991) Coexpression of vasopressin and oxytocin in hypothalamic 
supraoptic neurons of lactating rats. Endocrinology 129(4):1814-20. 
 
Milligan JF, Matteucci MD, Martin JC (1993) Current concepts in antisense drug design. 
J Med Chem 36:1923-1937. 
 
Mohr E, Bahnsen U, Kiessling C, Richter D (1988a) Expression of the vasopressin and 
oxytocin genes in rats occurs in mutually exclusive sets of hypothalamic neurons. 
FEBS Lett 242(1):144-8.  
 
Mohr E, Schmitz E, Richter D (1988b) A single rat genomic DNA fragment encodes 
both the oxytocin and vasopressin genes separated by 11 kilobases and oriented in 
opposite transcriptional directions. Biochimie 70(5):649-54.  
 
Monteith DK, Levin AA (1999)  Synthetic oligonucleotides: the development of 
antisense therapeutics. Toxicol Pathol 27(1):8-13. 
 
Murphy D, Carter D (1990) Vasopressin gene expression in the rodent hypothalamus: 




Murphy D, Waller S, Fairhall K, Carter DA, Robinson CA (1998) Regula tion of the 
synthesis and secretion of vasopressin. Prog Brain Res 119:137-43. 
 
Nemunaitis J, Holmlund JT, Kraynak M, et al (1999)  Phase I evaluation of ISIS 3521, 
an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with 
advanced cancer. J Clin Oncol 17(11):3586-95. 
 
Paxinos G,Watson C (1986) The rat brain in stereotaxic coordinates, 2.ed., Academic 
Press, New York p. 180. 
 
Paxinos G,Watson C (1997) The rat brain in stereotaxic coordinates. Compact third 
edition, 3.ed., Academic Press, San Diego (CD). 
 
Pestka S (1992) Antisense RNA: Hystory and perspective. In: Baserga R, Denhardt DT, 
eds. Antisense Strategies. New York: Ed. The New York Academic of Sciences; p. 
251-62. 
 
Peterson RP (1966) Magnocellular neurosecretory centers in the rat hypothalamus. J 
Comp Neurol 128(2):181-90. 
 
Phillips MI, Gyurko R (1997) Antisense oligonucleotides: New tools for physiology. 
News Physiol Sci 12: 99-105. 
 
 57 
Reeves WB, Andreoli TE (1992) The posterior pituitary and water metabolism. In: J.D. 
Wilson and D.W Foster (Eds), William´s Textbook of Endocrinology. WB Saunders, 
Philadelphia, PA, pp. 311-356. 
 
Renaud LP, Bourque CW (1991) Neurophysiology and neuropharmacology of 
hypothalamic magnocellular neurons secreting vasopressin and oxytocin. Prog 
Neurobiol 36(2):131-69. 
 
Rhodes CH, Morrell JI, Pfaff DW (1981) Immunohistochemical analysis of 
magnocellular elements in rat hypothalamus: distribution and numbers of cells 
containing neurophysin, oxytocin, and vasopressin. J Comp Neurol 198(1):45-64. 
 
Richter D (1988). Molecular events in expression of vasopressin and oxytocin and their 
cognate receptors. Am J Physiol 255:F207-F219. 
 
Schlingensiepen KH, Heilig M (1997) Gene function analysis and therapeutic 
prospects in Neurobiology. In: Schlingensiepen R, Brysch W, Schlingensiepen KH, 
eds. Antisense from technology to therapy. Blackwell Wissenchaft Berlin-Viena; 
p.187-223. 
 
Schlingensiepen R, Schlingensiepen KH (1997) Antisense 
oligodeoxynucleotides-Hyghly specific tools for basic research and pharmacotherapy. 
In: Schlingensiepen R, Brysch W, Schlingensiepen KH, eds. Antisense from 
technology to therapy. Blackwell Wissenchaft Berlin-Viena; p.3-28. 
 58 
 
Sharma HW, Narayanan R (1995) The therapeutic potential of antisense 
oligonucleotides. Bioessays 17(12):1055-63. 
 
Sharma HW, Narayanan R (1995) The therapeutic potential of antisense 
oligonucleotides. Bioessays 17(12):1055-63. 
 
Sherman TG, Day R, Civelli O, Douglass J, Herbert E, Akil H, Watson SJ (1988) 
Regulation of hypothalamic magnocellular neuropeptides and their mRNAs in the 
Brattleboro rat: coordinate responses to further osmotic challenge. J Neurosci 
8(10):3785-96. 
 
Skutella T, Montkowski A, Stohr T, et al (1994a) Corticotropin-releasing hormone 
(CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced 
anxiety in rats. Cell Mol Neurobiol  14(5):579-88. 
 
Skutella T, Probst JC, Engelmann M, Wotjak CT, Landgraf R, Jirikowski GF (1994b) 
Vasopressin antisense oligonucleotide induces temporary diabetes insipidus in rats. J 
Neuroendocrinol 6(6):626 
 
Skutella T, Probst JC, Caldwell JD, Pedersen CA, Jirikowski GF (1995) Antisense 
oligodeoxynucleotide complementary to oxytocin mRNA blocks lactation in rats. Exp 
Clin Endocrinol Diabetes  103(3):191-5. 
 
 59 
Sofroniew MV, Schrell U (1982) Long-term storage and regular repeated use of diluted 
antisera in glass staining jars for increased sensitivity, reproducibility, and convenience 
of single- and two-color light microscopic immunocytochemistry. J Histochem 
Cytochem 30(6):504-11. 
 
Sofroniew MV (1983) Morphology of vasopressin and oxytocin neurones and their 
central and vascular projections. Prog Brain Res 60:101-14. 
 
Soreq H, Seidman S (2000) Anti-sense approach to anticholinesterase therapeutics. 
Isr Med Assoc J 2 Suppl:81-5. 
 
Spampinato S, Canossa M, Carboni L, Campana G, Leanza G, Ferri S (1994) 
Inhibition of proopiomelanocortin expression by an oligodeoxynucleotide 
complementary to beta-endorphin mRNA. Proc Natl Acad Sci U S A 91(17):8072-6. 
 
Stein CA, Cheng YC (1993) Antisense oligonucleotides as therapeutic agents--is the 
bullet really magical? Science  261(5124):1004-12. 
 
Stein CA, Mori K, Loke SL, Subasinghe C, Shinozuka K, Cohen JS, Neckers LM (1988) 
Phosphorothioate and normal oligodeoxyribonucleotides with 5'-linked acridine: 
characterization and preliminary kinetics of cellular uptake. Gene 72(1-2):333-41. 
 
Swanson LW, Kuypers HG (1980) The paraventricular nucleus of the hypothalamus: 
cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal 
 60 
vagal complex, and spinal cord as demonstrated by retrograde fluorescence 
double-labeling methods. J Comp Neurol 194(3):555-70. 
 
Swanson LW, Sawchenko PE (1983) Hypothalamic integration: organization of the 
paraventricular and supraoptic nuclei. Annu Rev Neurosci 6:269-324. 
 
Szklarczyk A, Kaczmarek L (1995)  Antisense oligodeoxyribonucleotides: stability and 
distribution after intracerebral injection into rat brain. J Neurosci Methods 
60(1-2):181-7. 
 
Telleria-Diaz A (2000) Antisense targeting en Neurología. Rev  Neurol 31(8):762-9. 
 
Telleria-Diaz A, Grinevich VV, Jirikowski GF (2001) Colocalization of vasopressin and 
oxytocin in hypothalamic magnocellular neurons in water-deprived rats. Neuropeptides  
35(3-4):162-7 
 
Terashima Y, Kondo K, Oiso Y (1999) Administration of oxytocin affects vasopressin 
V2 receptor and aqaporin-2 gene expression in the rat.  Life Sci  64: 1447-53. 
 
TS´O POP, Aurellian L, Chang E, Miller PS (1992) Nonionic oligonucleotide analogs 
(Matagen) as anticodic agents in duplex and triplex formation. En Baserga R, 




van Esseveldt KE, Lehman MN, Boer GJ (2000) The suprachiasmatic nucleus and the 
circadian time-keeping system revisited. Brain Res Brain Res Rev 33(1):34-77. 
 
Van Kampen JM, McGeer EG, Stoessl AJ (2000) Dopamine transporter function 
assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity. 
Synapse 37(3):171-8. 
 
van Leeuwen FW, Verwer RW, Spence H, Evans DA, Burbach JP (1998) The 
magnocellular neurons of the hypothalamo-neurohypophyseal system display 
remarkable neuropeptidergic phenotypes leading to novel insights in neuronal cell 
biology. Prog Brain Res 119:115-26. 
 
Van Tol HH, Voorhuis DT, Burbach JP (1987) Oxytocin gene expression in discrete 
hypothalamic magnocellular cell groups is stimulated by prolonged salt loading. 
Endocrinology 120(1):71-6. 
 
Vandesande F, Dierickx K (1975) Identification of the vasopressin producing and of the 
oxytocin producing neurons in the hypothalamic magnocellular neurosecretroy system 
of the rat. Cell Tissue Res 164(2):153-62. 
Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature. 
372:333-335. 
 
Wagner RW (1995) The state of the art in antisense research. Nat Med  1(11):1116-8. 
 
 62 
Warzocha K, Wotowiec D (1997) Antisense strategy: biological utility and prospects in 
the treatment of hematological malignancies. Leuk Lymphoma 24:267-281. 
 
Weidner DA, Busch H (1994) Antisense phosphorothioate oligonucleotides direct both 
site-specific and nonspecific RNAse H cleavage of in vitro synthesized p120 mRNA. 
Oncol.Res 6:237-242. 
 
Weiss B, Zhou LW, Zhang SP, Qin ZH (1993) Antisense oligodeoxynucleotide inhibits 
D2 dopamine receptor-mediated behavior and D2 messenger RNA. Neuroscience  
55(3):607-12. 
 
West AP, Cooke BA (1991) A novel method to modulate desensitization and truncation 
of luteinizing hormone receptors using antisense oligodeoxynucleotides. Mol Cell 
Endocrinol 79(1-3):R9-14. 
 
Whitesell L, Geselowitz D, Chavany C, Fahmy B, Walbridge S, Alger JR, Neckers LM 
(1993)  Stability, clearance, and disposition of intraventricularly administered 
oligodeoxynucleotides: implications for therapeutic application within the central 
nervous system. Proc Natl Acad Sci U S A 90(10):4665-9. 
 
Williard R, Benz CC, Baxter JD, Kushner P, Hunt CA (1994) Paradoxical production of 
target protein using antisense RNA expression vectors. Gene 149(1):21-4. 
 
 63 
Xi D, Kusano K, Gainer H (1999)  Quantitative analysis of oxytocin and vasopressin 
messenger ribonucleic acids in single magnocellular neurons isolated from supraoptic 
nucleus of rat hypothalamus. Endocrinology 140(10):4677-82. 
 
Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov 
VV (1989) Mechanism of oligonucleotide uptake by cells: involvement of specific 
receptors? Proc Natl Acad Sci U S A 86(17):6454-8. 
 
Yuen AR, Halsey J, Fisher GA, et al (1999) Phase I study of an antisense 
oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with 
cancer. Clin Cancer Res  5(11):3357-63. 
 
Zhang M, Creese I (1993) Antisense oligodeoxynucleotide reduces brain dopamine D2 
receptors: behavioral correlates. Neurosci Lett 161(2):223-6. 
 
Zingg HH, Lefebvre D, Almazan G (1986)  Regulation of vasopressin gene expression 








Ich danke dem Deutschen Akademischen Austauschdienst DAAD für die 
Zuerkennung eines Stipendiums, das mir die Durchführung meiner Arbeit in Jena 
ermöglichte.  
 
Weiter danke ich  Herrn Prof. Jirikowski für die Vergabe des Themas und die 
Betreuung. Frau Günther und Frau Schönfeld danke ich für technische Unterstützung. 
Das Projekt selbst wurde vom IZKF, Schwerpunkt klinisch orientierte 
Neurowissenschaften, Projekt 1.2 gefördert. Bei den Tierexperimenten half Herr PD Dr. 
Juraj Culman vom Institut für Pharmakologie der Universität Kiel. Die 
Radioimmunoassays wurden im Labor von Herrn Prof. Dr. Rascher an der Kinderklinik 
der Universität Erlangen durchgeführt.  
 
Weiter danke ich Herrn M. Szabo für die Hilfe bei den photographischen Arbeiten. 
 
Mein besonderer Dank gilt aber meiner Familie, die mich ständig ermutigt hat, meinen 















Hiermit erkläre ich, dass mir die Promotionsprüfungsordnung der Medizinischen 
Fakultät der Friedrich-Schiller-Universität bekannt ist,  
 
ich die Dissertation selbst angefertigt habe und alle von mir benutzten Hilfsmittel, 
persönlichen Mitteilungen und Quellen in meiner Arbeit angegeben sind, 
 
mich Prof. Dr. Jirikowski  bei der Auswahl und Auswertung des Materials sowie bei der 
Herstellung des Manuskripts unterstützt hat,  
 
ich die Hilfe eines Promotionsberaters nicht in Anspruch genommen habe, dass Dritte 
weder unmittelbar noch mittelbar geldwerte Leistungen von mir für Arbeiten erhalten 
haben, die im Zusammenhang mit dem Inhalt der vorgelegten Dissertation stehen, 
 
dass ich die Dissertation noch nicht als Prüfungsarbeit für eine staatliche oder andere 
wissenschaftliche Prüfung eingereicht habe und 
 
dass ich die gleiche, eine in wesentlichen Teilen ähnliche oder eine andere 









Jena, den 31.03.2003 (Corrected copy)     Alejandro Telleria-Diaz 







Name :                                                          Alejandro Tellería-Díaz 
 
Geburtsdatum:                                          10. Januar 1969 
 









Medizinische Ausbildung : 
1986-1992 
 
Vorklinisch-theoretisch im "Instituto de Ciencias Básicas y 
Preclínicas  (ICBP)  Victoria de Girón", klinisch-chirurgisch 
in der medizinischen Fakultät des Krankenhauses "Calixto 
García", (Havanna). 







Resident der Neurologischen Abteilung des Krankenhauses 
"Hermanos Ameijeiras", mit Ausbildungsabschnitten im  
Institut für Neurologie und Neurochirurgie (Havanna). 
Staatsexamen am  Institut für Neurologie und Neurochirurgie 







HEUTE                 Arzt und Neurologe. 
 
Mitglied des Editorial Board der ”Revista de Neurología”  
(Barcelona – Spanien. http://www.revneurol.com/) 
Mitglied der Kubanischen Akademie der Wissenschaften. 
Abteilung: Zerebrovaskuläre Erkrankungen (SONECUB). 
Mitglied der Kubanischen Gesellschaft für Neurologie und 
Neurochirurgie. 








Assistierender Student der polyvalenten Intensivstation des 
Krankenhauses  "Calixto García"Hospital.   
1990-1992 (gleichzeitig) Assistierender Student in der Neurologischen Intensivstation 
des ”Centro Internacional de Restauración Neurológica” 
(CIREN). 
1992-1995 Neurologische Abteilung des "Hermanos Ameijeiras" 
Hospitals. 
April 1996 - Mai 1996 ”Stroke unit” in CIREN. 
Juni 1996 - Dezember 1996. Chef  der Neurologlischen Abteilung an der ”Clinic of the 
Basic Area” in CIREN (14 Betten) 
Januar 1997 - September 1998 Intensivestation ”Enrique Cabrera Hospital” 
Seit Januar 1999 Offizielles Mitglied des Editorial Board der ”Revista de 
Neurología” (Barcelona-Spanien). 
Oktober 1998 – Mai 2001 DAAD Stipendiat am Institut für Anatomie / Anatomie II an 
der Friedrich-Schiller Universität Jena 
Juni 2001- jetzt wissenschaftlicher Mitarbeiter am Institut für Physiologie I 
Abteilung Neurophysiologie der Friedrich-Schiller 
Universität Jena 
 
Hospital ”Hermanos Ameijeiras”. http://www.hha.sld.cu/ 
Centro Internacional de Restauración Neurológica (CIREN). http://www.sld.cu/instituciones/ciren/home.htm 





Sprachen:               Spanisch [Muttersprache] (*****) 
                                                                                        
                                                                                       Englisch  (****) 
 








Einführung in die Neurosonologie  (Oktober-November 2000; 6 Wochen). Neurologische Abteilung. Hospital 









To search in MEDLINE, please introduce: Telleria Diaz A, Telleria A,  or Telleria Diaz JA . 
 
1. Robinson MA, Veliz Y, Bergado J, Serrano T, Rosillo JC, Ivett C, Arana M, Quijano Z, Castellano O, Telleria A. 
Neuronal toxicity of human recombinant interleukin -2 in rats. Morphological and behavioral validation 
[Toxicidad neuronal de la IL-2 recombinante humana en ratas. Validación morfoconductual]. Rev Neurol. 1997 
Mar;25(139):452-6. 
 
2. Telleria A, Hernandez-Gonzalez E, Gomez-Fernandez L, Mustelier R, Calzada-Sierra D. Poems syndrome: a 
case report (report of  peculiar case) [ Síndrome de POEMS: a propósito de un caso]. Rev Neurol. 1997 
Apr;25(140):565-8. 
 
3. Hernandez-Gonzalez E, Abreu A, Mustelier R, Telle ria A, Calzada D, Gomez-Fernandez L. Cardiovascular 
changes in a group of patients with heredoataxia [Alteraciones cardiovasculares en un grupo de pacientes con 
Heredoataxia. Hallazgos clínicos, electro y ecocardiográficos]. Clinical, electrocardiographic and 
echocardiographic findings. Rev Neurol. 1997 Jun;25(142):847-9. 
 
4. Gomez-Fernandez L, Telleria-Diaz A. Physiopathology of amyotrophic lateral sclerosis: the contribution from 
transcranial magnetic stimulation [Fisiopatología de la ELA: contribuciones de la estimulación magnética 
transcraneal].  Rev Neurol. 1997 Jun;25(142):839-42. 
 
5. Telleria-Diaz A, Gomez-Fernandez L. Status epilepticus. Rev Neurol. 1997 Aug;25(144):1246-56. 
 
6. Telleria-Diaz JA, Rosello-Silva H, Gomez-Viera N. A longitudinal study of the course of Alzheimer type 
dementia [Estudio longitudinal sobre el curso de la Demencia Tipo Alzheimer]. Rev Neurol. 1997 
Oct;25(146):1551-6. 
 
7. Gomez-Viera N, Rodriguez-Silva H, Perez-Nellar J, Telleria-Diaz A, Nassiff A, Marquez M, Caceres M, 
Rivero-Arias E.Clinical characteristics of Cuban epidemic neuropathy [Caracterización clínica de la Neuropatía 
Epidémica Cubana]. Rev Neurol. 1997 Dec;25(148):1848-52. 
 
8. Telleria-Diaz A. Neurosciences without frontiers [Neurociencias sin fronteras]. Rev Neurol. 1998 
Apr;26(152):577-8. 
 
9. Telleria-Diaz A. Cuban epidemic of optic myeloneuropathy [Mieloneuropatia óptica epidémica cubana]. Rev 
Neurol. 1998 May;26(153):840. 
 
10. Gomez L, Fernandez A, Mustelier R, Calzada D, Vidal B, Telleria A. Evoked motor potentials in the diagnosis 
of conversion hysteria [Potenciales evocados motores en el diagnóstico de la histeria de conversión]. Rev Neurol. 
1998 May;26(153):839-40. 
 
11. Telleria-Diaz A. Apnea test to establish death based on brain criteria. [Prueba de apnea en la determinación de 
la muerte por criterios cerebrales]. Rev Neurol. 1998 Jul;27(155):108-10. 
 
12. Telleria-Diaz A, Garcia OD, Sanchez-Chavez JJ. The concept of "hemorrhage-ischemia" and its therapeutic 
implications [El concepto de ”hemorragia isquemia” y sus implicaciones terapéuticas]. Rev Neurol. 1998 
Jul;27(155):160-1. 
 
13. Garcia OD, Telleria-Diaz A, Sanchez-Chavez JJ. Carotid endarterectomy, endovascular treatment and ... 
neuroprotection "too"? [¿Endarterectomía carotídea, terapia endovascular, y...”además neuroprotección?] Rev 
Neurol. 1998 Jul;27(155):161-2. 
 
14. Telleria-Diaz A. Surgical treatment of hypertensive spontaneous intracerebral hemorrhage: procedure yet to be 
defined [Tratamiento quirúrgico de la hemorragia intracerebral espontánea del hipertenso: una conducta aun por 
definir]. Rev Neurol. 1998 Jul;27(155):162-3. 
 
15. Garcia OD, Telleria-Diaz A. Atrial fibrillation of non-valvular origin and anti-coagulation: a promising 
opportunity for the prevention of cerebral infarct... if there is  participation of those working in primary attention 
[La fibrilación auricular de etiología no valvular y la anticoagulación: una promisoria oportunidad para la 
prevención del infarto cerebral.... si es que el nivel de atención primaria participa en el esfuerzo]. Rev Neurol. 
1998 Sep;27(157):520-1. 
 
16. Telleria-Diaz A. Intensive neurology. Past, present, and future [Neurología intensiva. Pasado, presente y 
futuro]. Rev Neurol. 1998 Nov;27(159):830-2. 
 
17. Telleria-Diaz A, Garcia OD, Telleria -Diaz E. Critical illness polyneuropathy. Relevance of neurophysiological 
studies [Polineuropatía del paciente crítico. Relevancia de los estudios neurofisiológicos]. Rev Neurol. 1998 
Nov;27(159):873. 
 
18. Telleria Diaz A . Antisense targeting in neurology [Antisense Targeting en Neurología]. Rev Neurol. 2000 Oct 
16-31;31(8):762-9. 
 
19. Telleria-Diaz A, Culman J, Rascher W, Jirikowski GF. In vivo antisense targeting of Hypothalamic vasopressin  
neurons results in coexpression of vasopressin and oxytocin. Cell. Mol. Biol 2000; 46: 245. (abstract). 
 
20. Tellería A, Moltó JM, Frutos T, Medrano M, et al. Neurosonological evaluation of transient global amnesia. 
Cerebrovasc Dis 2001; 11(suppl 3): 46 (abstract). 
 
21. Telleria Diaz A, Calzada Sierra DJ. Overdiagnosis in the epidemic of neuropathy in Cuba. Rev Neurol. 2001 
Sep 16;33(6):597-8.  
 
22. Jirikowski GF, Telleria-Diaz A, Grinevich VV. Functional plasticity of vasopressinergic and oxytocinergic 
systems in the rat hypothalamus. European Journal of Anatomy 2001; 5(suppl 1): 27. (abstract). 
 
23. Telleria-Diaz A, Grinevich VV , Jirikowski GF. Colocalization of vasopressin and oxy tocin in hypothalamic 
magnocellular neurons in water deprived rats. Neuropeptides 2001; 35 (3&4), 162-167. 
 
24. Calzada-Sierra DJ, Tellería-Diaz A. Cuban optic myeloneuropathy: Discrepancies in relation to a possible viral 
etiology. Rev Neurol 2001; 33(8):798-800. 
 
25. Calzada-Sierra DJ, Tellería-Diaz A. Reply to Dr. Rosaralis Santiesteban Freixas  about her comments on the 
article  ¨ Overdiagnosis in the epidemic of neuropathy in Cuba ¨. Rev Neurol (in press). 
 
26. Tellería-Diaz A, Calzada-Sierra DJ. Gu illain-Barré Syndrome [Síndrome de Guillain-Barré]. Rev Neurol (in 
press). 
 
27. Bär KJ, Tellería-Díaz A, Teschner P, Vázquez E, Schaible HG, Ebersberger A. The changing role of spinal 
prostaglandin E2 during inflammation. In process of submission. 
 
28. Telleria-Diaz A, Culman J, Rascher W, Jirikowski G. F. In vivo antisense targeting of rat hypothalamic 
vasopressin neurons results in coexpression of vasopressin and oxytocin. In process of submission. 
 
 
 
 
